Beijing InnoCare Pharma reported China 's NMPA approved its BTK inhibitor for three indications: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). All three indications are for patients who have relapsed or refractory forms of the disease. Orelabrutinib will be the first InnoCare candidate to be commercialized. Earlier this year, InnoCare completed a $288 million IPO in Hong Kong that valued the company at $1 billion. More details.... Stock Symbol: (HK: 09969) Share this with colleagues: // //